Difference between revisions of "Paroxetine-clomipramine"
From Psychiatrienet
| Line 11: | Line 11: | ||
* '''Day 15:''' increase dosage of clomipramine to 50-100 mg/day. | * '''Day 15:''' increase dosage of clomipramine to 50-100 mg/day. | ||
* '''Day 28:''' if necessary, increase dosage of clomipramine. | * '''Day 28:''' if necessary, increase dosage of clomipramine. | ||
| − | |||
| info = | | info = | ||
* Paroxetine slows the metabolism of clomipramine via CYP2D6. }} | * Paroxetine slows the metabolism of clomipramine via CYP2D6. }} | ||
Revision as of 07:53, 24 July 2009
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from paroxetine to clomipramine.[1] [2]
Stop paroxetine - Day 0: gradually reduce dosage of paroxetine to a maximum of 20 mg/day when this dosage is > 20 mg/day.
- Day 1: reduce dosage of paroxetine to a maximum of 10 mg/day.
- Day 8: stop dosage of paroxetine.
Start clomipramineCaution is necessary.
- Day 8: start administration of clomipramine in a low dosage of 25-50 mg/day.
- Day 15: increase dosage of clomipramine to 50-100 mg/day.
- Day 28: if necessary, increase dosage of clomipramine.
More information- Paroxetine slows the metabolism of clomipramine via CYP2D6.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
